Delayed gadoxetate MRI improves liver tumor delineation during MR-guided adaptive SBRT
Gadoxetate-enhanced MRI at 20–30 minutes improved liver tumor visibility and increased interobserver contour agreement from Dice 0.84 to 0.92.
Gadoxetate-enhanced MRI at 20–30 minutes improved liver tumor visibility and increased interobserver contour agreement from Dice 0.84 to 0.92.
Across 323 treatment CBCT scans, HyperSight improved image completeness and dose agreement compared with iterative CBCT, while contouring reliability remained inconsistent.
In 15 pelvic osteosarcoma plans, LET optimization reduced LEM-I versus mMKM target dose discrepancies by up to 9% of prescription, with modest robustness penalties.
Among 879 SRS programs, 91% treated multiple lesions, while only 18.8% reported additional machine-specific QA for multi-lesion treatments.
A simplified density-assignment workflow achieved 99.2% gamma agreement in retrospective liver SABR plans and 98.8% in the first five trial patients.
A 90-item benchmark found O3 represented 74% of radiotherapy-specific elements, supporting selective mapping across clinical, registry, and research data standards.
In 50 pancreatic SBRT fractions, expert recontouring identified duodenal dose-limit exceedances in two patients despite largely preserved target coverage.
On 87 verification CTs, proton plans spared heart, lung, and breast dose but showed target undercoverage in six patients versus one with VMAT.
Across 24 expert sessions, AI-assisted scribble editing reduced median contour refinement time by 70% while maintaining similar final contour quality.
Contrast-enhanced CT altered mean lung electron density by approximately 12–13%, but bulk-density MR-Linac dose recalculations showed relatively small differences.
CT-generated synthetic MRI achieved mean Dice scores of 0.58 for primary and 0.73 for nodal tumor contours in ten test patients.
In ten head and neck cancer plans, proton arc therapy reduced simulated mean circulating blood dose from 0.563 to 0.483 Gy(RBE).
AI-generated partial breast plans met all constraints in six of seven end-to-end cases, but fixed beam geometry caused frequent heart-dose violations.
Nearly half of reviewed meningioma RT cases required contour resubmission despite pretrial credentialing, supporting prospective patient-level quality assurance.
A particle-therapy second-check platform modeled delivery and variable RBE, but its reported proton dose comparison achieved 84.9% gamma agreement and required review.